Inside Modern Biotech
Researchers in Brazil ran a randomized controlled trial on 80 women undergoing chemotherapy for breast cancer. One group took 2,000 IU of vitamin D daily. The other took a placebo. After six months, 43% of the vitamin D group had no cancer left by the time of surgery. In the placebo group, only 24% did. That is a 79% relative difference. From a supplement that costs a few dollars a month. In this episode, we break down what the study actually found, why the numbers need careful reading, and what a second independent trial from Turkey with 227 patients adds to the picture. We explain what vitamin D actually does inside cancer cells: how it pushes them toward self-destruction, cuts off their blood supply, and may make chemotherapy more effective. We also cover why so many breast cancer patients are deficient before treatment even begins, what dose was used and why it is considered safe, and what needs to happen before this changes standard clinical practice. This is not a story about a miracle supplement. It is a story about a real signal in real data, a biologically plausible mechanism, and what it could mean for patients in health systems where expensive cancer drugs are out of reach. Source: Omodei et al., Nutrition and Cancer, 2025. DOI: 10.1080/01635581.2025.2480854 Supporting: Özkurt et al., World Journal of Surgery, 2025. DOI: 10.1002/wjs.12587
6 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Inside Modern Biotech!